Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese

doi:10.4254/wjh.v11.i6.531

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6387)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

427

WORD

253

HTML

3100

Figures (1-2)

146

Tables (1-2)

164

Sum=4090

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

743

Download

1554

Sum=2297

Jun 27, 2019 (publication date) through May 8, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jun 27, 2019; 11(6): 531-541
Published online Jun 27, 2019. doi: 10.4254/wjh.v11.i6.531

Table 1 Patient baseline characteristics

	Rifaximin (n = 38)	Control (n = 38)	P value
Age (yr)	69 (40-85)	69.5 (42-90)	0.934
Sex (female/male)	17 (44.7%)/21 (55.3%)	11 (28.9%)/27 (71.1%)	0.234
BMI (kg/m²)	24.78(18.67-35.88)	23.1 (15.5-30.1)	0.035
Etiology (HBV/HCV/Alcohol/NASH)	7 (18.4%)/5 (13.2%)/13 (34.2%)/5 (13.2%)	4 (10.5%)/14 (36.8%)/9 (23.7%)/3 (7.9%)	0.107
Child-Pugh A/B/C	15 (39.5%)/15 (39.5%)/8 (21.1%)	20 (52.6%)/ 17 (44.7%)/1 (2.6%)	0.051
ALBI Grade	1(2.6%) /27 (71.1%) /10 (26.3%)	22 (57.9%)/15 (39.5%)/1(2.6%)	< 0.001
MELD Score¹	6 (2-17)	9 (0-22)	0.205
ALT (IU/L)¹	24.5 (8.0-105.0)	31.5 (8.0-1490)	0.109
AST (IU/L)¹	39.5 (20.0-136.0)	45 (15-1041)	0.426
GGTP (IU/L)¹	35.5 (11.0-558.0)	64 (14-506)	0.055
Serum ammonia	104 (59-297)	52 (23-89)	< 0.001
Albumin (g/dL)¹	3.0 (2.1-4.4)	4.05 (2.4-5.0)	< 0.001
Total bilirubin (mg/dL)¹	1.65 (0.4-4.7)	1.0 (0.4-8.6)	0.002
Platelet count (×103/μL)¹	8.7 (4.8-27.9)	12.3 (2.3-30.2)	0.023
Prothrombin activity (%)	60 (38-133)	69 (14-108)	0.066
AFP (ng/mL)¹	4.3 (1.0-3375)	6.25 (1.3-385.5)	0.065
DCP (mAU/mL)¹	37 (15-3178)	25 (11-11688)	0.383
Fibrosis 4 index¹	5.61 (1.71-15.1)	4.25 (1.2-33.4)	0.117
MRE (kPa)¹	5.04 (3.00-11.11)	4.86 (3.36-12.50)	0.748
SWE (kPa)¹	23.1 (8.3-56)	16.8 (7.0-36.8)	< 0.001
History of overt hepatic encephalopathy	12 (31.6%)	0 (0%)	< 0.001
HCC	9 (23.7%)	12 (31.6%)	0.442
Ascites	11 (29.0%)	10 (26.3%)	0.834
Esophageal varices	27 (71.1%)	23 (60.5%)	0.469
Max diameter of portosystemic shunts (mm)	7.6 (1.7-18.5)	4.2 (1.6-10.9)	< 0.001
Number of portosystemic shunts (0,1/2-)	8 (22.2%)/28 (77.8%)	24 (63.2%)/14 (36.8%)	0.001
Lactulose	29 (76.3%)	6 (15.8%)	< 0.001
BCAA	24 (63.2%)	14 (36.8%)	0.038
Sarcopenia	17 (44.7%)	17 (44.7%)	1
Follow up period (wk)¹	61 (24-91)	91 (5-120)	< 0.001

¹Values are expressed as median (range). BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis; ALBI score: Albumin bilirubin score; MELD score: Model for End-Stage Liver Disease score; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGTP: Gamma-glutamyl transpeptidase; AFP: Alpha fetoprotein; DCP: Des-gamma carboxyprothrombin; MRE: Magnetic resonance elastography; SWE: Shear wave elastography; HCC: Hepatocellular carcinoma; BCAA: Branched-chain amino acid.

Table 2 Risk factors for insufficient improvement of serum ammonia after rifaximin treatment

Category	HR (95%CI)	P value
Category	HR (95%CI)	P value
Univariate analysis
Age (yr at MRE)
< 70	1
≥ 70	2.2 (0.56-8.7)	0.26
Sex
female	1
male	0.491 (0.128-1.88)	0.30
BMI (kg/m²)
< 28	1
≥ 28	0.42 (0.094-1.85)	0.25
AST (IU/L)
< 36	1
≥ 36	0.372 (0.094-1.47)	0.16
ALT (IU/L)
< 30	1
≥ 30	0.43 (0.11-1.7)	0.23
GGTP (IU/L)^a
< 42	1
≥ 42	0.71 (0.18-2.87)	0.64
Albumin (g/dL)
≥ 3.0	1
< 3.0	3.3 (0.83-13)	0.091
Total bilirubin (mg/dL)
< 1.4	1
≥ 1.4	3.0 (0.76-12)	0.12
Platelet count (×10³/μL)
≥ 6.8	1
< 6.8	4.1 (0.67-25)	0.13
Prothrombin activity (%)
< 58	1	0.13
≥ 58	3.0 (0.72-13)
AFP (ng/mL)
< 6.5	1
≥ 6.5	3.25 (0.55-19)	0.20
DCP (mAU/mL)
< 18	1
≥ 18	3.6 (0.57-23)	0.17
Ascites
Absent	1	0.16
Present	2.5 (0.70-8.8)
Esophageal varices
Absent	1	0.42
Present	1.8 (0.43-7.5)
History of hepatic encephalopathy
Absent	1	0.11
Present	3.6 (0.77-16)
HCC¹
Absent	1	0.72
Present	0.75 (0.16-3.6)
Sarcopenia
Absent	1	0.49
Present	1.64 (0.41-6.6)
Child-Pugh Score		0.061
< 7	1
≥ 7	3.9 (0.94-16)
ALBI Score
< -1.6	1
≥ -1.6	5.3 (1.1-25)	0.033
MELD Score
< 12	1	0.13
≥ 12	3.0 (0.72-13)
Fibrosis 4 index
< 8.3	1
≥ 8.3	0.42 (0.094-1.9)	0.25
MRE (kPa)
< 5.0	1	0.43
≥ 5.0	1.63 (0.40-8.3)
SWE (kPa)
< 17.7	1
≥ 17.7	3.0 (0.65-14)	0.16
Max diameter of portosystemic shunt
< 8.0	1
≥ 8.0	6.8 (1.4-33)	0.017
Number of portosystemic shunt systems
0,1	1	0.68
2-4	1.36 (0.32-5.9)
Multivariate analysis
Max diameter of portosystemic shunt
< 8.0	1
≥ 8.0	5.5 (1.1-28)	0.039
ALBI Score		0.16
< -1.6	1
≥ -1.6	3.3 (0.62-18)

BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGTP: Gamma-glutamyl transpeptidase; AFP: Alpha fetoprotein; DCP: Des-gamma carboxyprothrombin; HCC: Hepatocellular carcinoma; MELD Score: Model for End-Stage Liver Disease score; ALBI Score: Albumin-bilirubin score; MRE: Magnetic resonance elastography; SWE: Shear wave elastography.

Citation: Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541
URL: https://www.wjgnet.com/1948-5182/full/v11/i6/531.htm
DOI: https://dx.doi.org/10.4254/wjh.v11.i6.531